Skip to main content
editorial
. 2019 Feb 22;120(6):577–578. doi: 10.1038/s41416-019-0388-7

Fig. 1.

Fig. 1

Sensitivity of KIT mutations to approved TKIs. green = sensitive; red = resistant; IM = imatinib; SU = sunitinib; RE = regorafenib; ABD = ATP-binding domain; AL = activation loop. Not shown: mutations in amino acid D816 (exon 17) are resistant to all TKIs (modified from ref 7)